Abstracts tagged "Myocarditis"

Abstract Number: 1111 • ACR Convergence 2025
Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Maja Ivanovic¹, Daming Shao², Andrew Wang³, Craig Smuda² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Chicago Pritzker School of Medicine, Chicago, IL
Background/Purpose: Immune checkpoint inhibitor (ICI) induced myositis is the ICI rheumatic toxicity with the greatest case mortality rate, especially when associated with myocarditis and/or myasthenia…
Abstract Number: 0696 • ACR Convergence 2025
Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
Jeska de Vries-Bouwstra¹, Jingjing He², Xu Wang², Saad Ahmed², Jeroen J. Bax² and Nina Ajmone Marsan², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Myocardial involvement in systemic sclerosis (SSc) represents a severe complication with a poor prognosis; however, compromised cardiac function also heightens the risk of life-threatening…
Abstract Number: 0887 • ACR Convergence 2025
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Runci Wang¹, Chunyan Xiang², Adrien Procureur³, Julian Sanchez-Dal Cin³, Qing Wang⁴, Xinyue Lian⁵, Michelle Rosenzwajg³, Yves Allenbach⁶, Deepak Rao⁷, Qiong Fu⁸, Nan Shen⁹, Joe-Elie Salem³ and Shuang Ye¹⁰, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), shanghai, China (People's Republic), ³Sorbonne Université, Paris, France, ⁴Zhongshan Hospital, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, China (People's Republic), ⁶SORBONNE UNIVERSITE, Paris, France, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Renji Hospital, Shanghai, Shanghai, China, ⁹Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ¹⁰Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies for cancer can induce immune-related adverse events (irAEs) involving musculoskeletal (MSK) systems. ICI myotoxicity (ICI-M) can present as a…
Abstract Number: 2651 • ACR Convergence 2025
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Laura Ross¹, Andrew Burns², Andre La Gerche³, Dylan Hansen⁴, Gerry Coghlan⁵, Wendy Stevens⁶, David Prior⁷, Alan Pham⁸, Penelope McKelvie⁴, Chiara Bellocchi⁹, Yolanda Braun Moscovici¹⁰, Cosimo Bruni¹¹, Patricia E. Carreira¹², Tracy Frech¹³, Sabrina Hoa¹⁴, Marie Hudson¹⁵, Vivien Hsu¹⁶, Marco Matucci-Cerinic¹⁷, Benjamin Medina Fonseca¹⁸, Andrea Low¹⁹, Sue-Ann Ng¹⁹, Tatiana Rodriguez-Reyna²⁰, Joanne Sahhar²¹, Mohamed Talaat²², Susanna Proudman²³, Alessandra Vacca²⁴, Murray Baron²⁵ and Mandana Nikpour²⁶, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Hospital Melbourne, Fitzroy, Australia, ³St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁵Royal Free Hospital, London, United Kingdom, ⁶St Vincent's Hospital Melbourne & University of Melbourne, Fitzroy, Australia, ⁷University of Melbourne, Parkville, Australia, ⁸Alfred Hospital, Melbourne, Australia, ⁹University of Milan, Milan, Italy, ¹⁰Rambam Heath Care Campus, Haifa, Israel, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹³Vanderbilt University Medical Center, Nashville, TN, ¹⁴University of Montreal, Brossard, QC, Canada, ¹⁵McGill University, Montréal, QC, Canada, ¹⁶Rutgers- RWJ Medical School, South Plainfield, NJ, ¹⁷University San Raffaele Milano, Milano, Milan, Italy, ¹⁸Universidad Nacional Autonoma de Mexico, Monterry, Mexico, ¹⁹Singapore General Hospital, Singapore, Singapore, ²⁰Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²¹Monash Health, Melbourne, Victoria, Australia, ²²Augusta Health, Charlottesville, VA, ²³Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ²⁴University and AOU of Cagliari, Monserrato, Italy, ²⁵McGill University, Montreal, Canada, ²⁶University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: Systemic sclerosis (SSc) heart involvement (SHI) is a serious disease manifestation associated with high mortality. This study presents newly developed classification criteria to enable…
Abstract Number: 2386 • ACR Convergence 2025
Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Braden Zeno¹, Shane Bruckner², kassidy Banford³, Hannah Bulgart⁴, Stacy Ardoin⁵, noah weisleder⁴ and Wael Jarjour⁶, ¹Ohio State University, upper arlington, OH, ²OSU, Columbus, OH, ³Loyola University Chicago, Columbus, OH, ⁴University of Kentucky, Lexington, KY, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the heart. Recent studies attribute…
Abstract Number: 1856 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
Ayla Nadja Stuetz¹, Giacomo de Luca², Alexandru-Emil Matei³, Yi-Nan Li⁴, Veronica Batani², Tim Filla⁵, Aleix Rius Rigau⁶, Bilgesu Safak Tümerdem¹, Cosimo Bruni⁷, Maike Büttner-Herold⁸, Stefania Rizzo⁹, Monica De Gaspari⁹, Markus Eckstein¹⁰, Georg Schett¹¹, Cristina Basso⁹, Jörg Distler¹², Marco Matucci-Cerinic¹³ and Andrea-Hermina Györfi¹⁴, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ²Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany, ⁹Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, ¹⁰Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹³University San Raffaele Milano, Milano, Milan, Italy, ¹⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Primary heart involvement (pHI) is one of the leading causes of death in systemic sclerosis (SSc). However, the cellular and molecular pathomechanisms of SSc-pHI…
Abstract Number: 1151 • ACR Convergence 2025
A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study
Chelsea Guan¹, Dana Nachawati¹, Amir Daneshvar¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹, Vicky Nahra³ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Sarcoidosis is a systemic autoimmune disease with multiorgan involvement. In this study, we analyzed the differences in characteristics in patients with sarcoid myocarditis (cardiac…
Abstract Number: 1113 • ACR Convergence 2025
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Qi Wang¹, Zhiting Tang² and Lei Deng³, ¹Metrohealth System/Case Western Reserve University, Cleveland, OH, ²Unity Hospital, Rochester, NY, ³Fred Hutchinson Cancer Center, Seattle, WA
Background/Purpose: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but life-threatening immune-related adverse event (irAE), with a mortality rate of 30–50%. Most available evidence comes…
Abstract Number: 0313 • ACR Convergence 2024
Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Sehreen Mumtaz¹, Jayesh Valecha², Andy Abril³, Florentina Berianu³, Benjamin Wang⁴, Ronald Butendieck⁴, anushka Irani², carolyn mead harvey² and Vikas Majithia², ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Jacksonville, FL
Background/Purpose: Sarcoidosis, characterized by non-necrotizing granulomatous inflammation, is a multisystem disease with an unpredictable disease spectrum. An estimated 5% of sarcoidosis patients have clinically evident…
Abstract Number: 0322 • ACR Convergence 2024
Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging
Julie Paik¹, Shadi Ayoumi², Ghazal Zandieh², Cody Calhoun², Caoilfhionn Connolly², Lisa Christopher-Stine¹, Christopher Mecoli¹, Myma Albayda², Eleni Tiniakou³, Nisha Gilotra², Stefan Zimmerman² and Bharath Venkatesh², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Lutherville Timonium, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its association with poor outcomes such as heart failure and sudden cardiac death. It…
Abstract Number: 0656 • ACR Convergence 2024
Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
María del Carmen Zamora-Medina¹, Erik Cimé-Aké², Emilio G. Lazarini², Wallace Rafael A. Muñoz-Castañeda³ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Perinatología "Isidro Espinoza de los Reyes". Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Hospital Medica Sur. Rheumatology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: Limited information about lupus myocarditis (LM) comes from small case series. The aim of our study is to describe and compare clinical characteristics, cardiac…
Abstract Number: 0996 • ACR Convergence 2024
Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition
Enelle Mevorach, Adi Tabib and Dror Mevorach, Hadassah-University Hospital, Jerusalem, Israel
Background/Purpose: Following Pfizer-BioNTech BNT162b2 vaccine authorization, Israel initiated a nationwide COVID-19 vaccination campaign. The vaccine caused a higher incidence of myocarditis in young males. Here,…
Abstract Number: 1165 • ACR Convergence 2024
Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Julie Paik¹, Kevin Bermea², Carolina Duque³, Monica Mugnier³ and Luigi Adamo¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Cardiology, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Cardiac involvement, such as myocarditis, in idiopathic inflammatory myopathies (IIM) is a negative prognostic factor associated with increased mortality. The gold standard for myocarditis…
Abstract Number: 1995 • ACR Convergence 2024
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
Kaitlin McCarter¹, Xiaosong Wang², Senada Arabelovic¹, Nicole LeBoeuf¹, Elizabeth Buchbinder³, Lydia Gedmintas¹, Lindsey MacFarlane⁴, Deepak Rao⁵, Nancy Shadick², Elad Sharon³, Brittany Weber⁶, Anju Nohria¹, Ellen Gravallese⁷ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Brigham and Women's Hospital, Hanover, NH, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) antagonize CTLA-4, PD-1, PD-L1, and Lag-3 to stimulate the immune system to treat cancer but may also cause immune-related adverse…
Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].